T4 Report* Metabolomics in toxicology and preclinical research

Altex

Volumn 30, Issue 2, 2013, Pages 209-225

  Ramirez, Tzutzuy ^a   Daneshian, Mardas ^b   Kamp, Hennicke ^a   Bois, Frederic Y ^c   Clench, Malcolm R ^d   Coen, Muireann ^e   Donley, Beth ^f   Fischer, Steven M ^g   Ekman, Drew R ^h   Fabian, Eric ^a   Guillou, Claude ⁱ   Heuer, Joachim ^j   Hogberg, Helena T ^k   Jungnickel, Harald ^j   Keun, Hector C ^e   Krennrich, Gerhard ^a   Krupp, Eckart ^l   Luch, Andreas ^j   Noor, Fozia ^m   Peter, Erik ⁿ   Riefke, Bjoern ^o   Seymour, Mark ^p   Skinner, Nigel ^q   Smirnova, Lena ^j,k   Verheij, Elwin ^r   Wagner, Silvia ⁿ   Hartung, Thomas ^b   Van Ravenzwaay, Bennard ^a   Leist, Marcel ^b,s   more..

^a BASF SE   (Germany)

^b UNIVERSITY OF KONSTANZ   (Germany)

^c UNIVERSITÉ DE TECHNOLOGIE DE COMPIÈGNE   (France)

^d SHEFFIELD HALLAM UNIVERSITY   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f Stemina Biomarker Discovery Inc   (United States)

^g AGILENT TECHNOLOGIES   (United States)

^h U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

ⁱ JOINT RESEARCH CENTRE   (Italy)

^j FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

^k JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^l SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^m SAARLAND UNIVERSITY   (Germany)

ⁿ Metanomics GmbH   (Germany)

^o BAYER PHARMA AG   (Germany)

^p JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^q AGILENT TECHNOLOGIES   (United Kingdom)

^r TNO   (Netherlands)

^s Doerenkamp Zbinden Lab for In Vitro Toxicology and Biomedicine   (Germany)

more..

Author keywords

Metabolomics; Preclinical research; Regulatory toxicology; Toxicology

Indexed keywords

ANTIBODY SPECIFICITY; ARTICLE; ARTIFACT; BIOLOGY; CELL CULTURE; CELL INTERACTION; CROSS FERTILIZATION; DEVELOPMENTAL TOXICITY; FOOD INTAKE; GLYCOLYSIS; HUMAN; IN VITRO STUDY; METABOLISM; METABOLOMICS; MOLECULAR BIOLOGY; NONHUMAN; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SAFETY; SIGNAL NOISE RATIO; SPECIES DIFFERENCE; TARGET ORGAN; TOXICOLOGY; TRANSCRIPTOMICS; TRANSGENIC ORGANISM; TRANSGENIC PLANT; ANIMAL; BIOLOGICAL MODEL; METHODOLOGY; PREDICTIVE VALUE; REPRODUCIBILITY; TOXICITY TESTING;

ANIMALS; HUMANS; METABOLOMICS; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TOXICITY TESTS;

EID: 84877593138     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.14573/altex.2013.2.209     Document Type: Article

References (82)

1. Andersen, M. E., Clewell, H. J., Carmichael, P. L., et al. (2011). Can case study approaches speed implementation of the NRC report: "Toxicity testing in the 21st century: a vision and a strategy?" ALTEX 28, 175-182.
2. Balcke, G. U., Kolle, S. N., Kamp, H., et al. (2011). Linking energy metabolism to dysfunctions in mitochondrial respiration - a metabolomics in vitro approach. Toxicol Lett 203, 200-209.
3. Basketter, D. A., Clewell, H., Kimber, I., et al. (2012). A roadmap for the development of alternative (non-Animal) methods for systemic toxicity testing - t4 report. ALTEX 29, 3-91.
4. Bhattacharya, S., Zhang, Q., Carmichael, P. L., et al. (2011). Toxicity testing in the 21st century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS One 6, e20887.
5. Blaauboer, B. J., Boekelheide, K., Clewell, H. J., et al. (2012). The use of biomarkers of toxicity for integrating in vitro hazard estimates into risk assessment for humans. ALTEX 29, 411-425.
6. Boekelheide, K. And Andersen, M. E. (2010). A mechanistic redefinition of adverse effects - a key step in the toxicity testing paradigm shift. ALTEX 27, 243-252.
7. Bouhifd, M., Hartung, T., Hogberg, H. T., et al. (2013). Review: Toxicometabolomics. J Appl Toxicol, in press.
8. Bundy, J. G., Sidhu, J. K., Rana, F., et al. (2008). "Systems toxi cology" approach identifies coordinated metabolic responses to copper in a terrestrial non-model invertebrate, the earthworm Lumbricus rubellus. BMC Biol 6, 25.
9. Cascante, M. And Marin, S. (2008). Metabolomics and fluxomics approaches. Essays Biochem 45, 67-81.
10. Cavill, R., Kamburov, A., Ellis, J. K., et al. (2011). Consensus-phenotype integration of transcriptomic and metabolomic data implies a role for metabolism in the chemosensitivity of tumour cells. PLoS Comput Biol 7, e1001113.
11. Clayton, T. A., Lindon, J. C., Cloarec, O., et al. (2006). Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 440, 1073-1077.
12. Coecke, S., Balls, M., Bowe, G., et al. (2005). Guidance on good cell culture practice. A report of the second ECVAM task force on good cell culture practice. Altern Lab Anim 33, 261-287.
13. Coen, M., Want, E. J., Clayton, T. A., et al. (2009). Mechanistic aspects and novel biomarkers of responder and non-responder phenotypes in galactosamine-induced hepatitis. J Proteome Res 8, 5175-5187.
14. Dieterle, F., Sistare, F., Goodsaid, F., et al. (2010). Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 28, 455-462.
15. Ebbels, T. M., Keun, H. C., Beckonert, O. P., et al. (2007). Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach. J Proteome Res 6, 4407-4422.
16. EC (2011). European perspectives in personalised medicine, Conference Summary Report. 12-13 May 2011, Brussels, Belgium. http://ec.europa.eu/research/ health/pdf/personalised-medicine-conference-report-en.pdf
17. ECETOC (2008). Workshop on the application of 'omic technologies in toxicology and ecotoxicology: Case studies and risk assessment. Workshop report No 11.
18. ECETOC (2010). Workshop on omics in (eco)toxicology: Case studies and risk assessment. Workshop report No 19.
19. Falsig, J., Porzgen, P., Lotharius, J., et al. (2004). Specific modulation of astrocyte inflammation by inhibition of mixed lineage kinases with CEP-1347. J Immunol 173, 2762-2770.
20. Forgacs, A. L., Kent, M. N., Makley, M. K., et al. (2012). Comparative metabolomic and genomic analyses of TCDD-elicited metabolic disruption in mouse and rat liver. Toxicol Sci 125, 41-55.
21. Fuchs, T. C. And Hewitt, P. (2011). Biomarkers for drug-induced renal damage and nephrotoxicity-An overview for applied toxicology. AAPS J 13, 615-631.
22. Gantner, F., Leist, M., Kusters, S., et al. (1996). Tcell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. Exp Cell Res 229, 137-146.
23. Haase, A., Arlinghaus, H. F., Tentschert, J., et al. (2011). Application of laser postionization secondary neutral mass spectrometry/time-of-flight secondary ion mass spectrometry in nanotoxicology: visualization of nanosilver in human macrophages and cellular responses. ACS Nano 5, 3059-3068.
24. Hartung, T., Balls, M., Bardouille, C., et al. (2002). Good cell culture practice. ECVAM good cell culture practice task force report 1. Altern Lab Anim 30, 407-414.
25. Hartung, T. (2007). Food for thought ... on cell culture. ALTEX 24, 143-152.
26. Hartung, T. And Leist, M. (2008). Food for thought ... on the evolution of toxicology and the phasing out of animal testing. ALTEX 25, 91-102.
27. Hartung, T. (2009a). Food for thought ... on evidence-based toxicology. ALTEX 26, 75-82.
28. Hartung, T. (2009b). Toxicology for the twenty-first century. Nature 460, 208-212.
29. Hartung, T. And McBride, M. (2011). Food for thought ... on mapping the human toxome. ALTEX 28, 83-93.
30. Hartung, T., van Vliet, E., Jaworska, J., et al. (2012). Systems toxicology. ALTEX 29, 119-128.
31. Hecker, M. And Hollert, H. (2011). Endocrine disruptor screening: regulatory perspectives and needs. Environmental Sciences Europe 23, 15.
32. Henn, A., Lund, S., Hedtjarn, M., et al. (2009). The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 26, 83-94.
33. Henn, A., Kirner, S., and Leist, M. (2011). TLR2 hypersensitivity of astrocytes as functional consequence of previous inflammatory episodes. J Immunol 186, 3237-3247.
34. Hirt, U. A., Gantner, F., and Leist, M. (2000). Phagocytosis of nonapoptotic cells dying by caspase-independent mechanisms. J Immunol 164, 6520-6529.
35. Holmes, C., McDonald, F., Jones, M., et al. (2010). Standardization and omics science: technical and social dimensions are inseparable and demand symmetrical study. OMICS 14, 327-332.
36. Ingelman-Sundberg, M. (2001). Genetic variability in susceptibility and response to toxicants. Toxicol Lett 120, 259-268.
37. Judson, R., Kavlock, R., Martin, M., et al. (2013). Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX 30, 51-56.
38. Jungnickel, H. And Luch, A. (2012). A personalized life: biomarker monitoring from cradle to grave. EXS 101, 471-498.
39. Jungnickel, H., Tentschert, J., and Luch, A. (2012). Monitoring oxidative stress biomarkers in the lipidome: is there a roadmap for "human inspection"? Curr Mol Med 12, 716-731.
40. Kadereit, S., Zimmer, B., van Thriel, C., et al. (2012). Compound selection for in vitro modeling of developmental neurotoxicity. Front Biosci 17, 2442-2460.
41. Kim, J. Y., Kim, Y. G., and Lee, G. M. (2012). CHO cells in biotechnology for production of recombinant proteins: current state and further potential. Appl Microbiol Biotechnol 93, 917-930.
42. Klein, S. And Heinzle, E. (2012). Isotope labeling experiments in metabolomics and fluxomics. Wiley Interdiscip Rev Syst Biol Med 4, 261-272.
43. Kleinstreuer, N. C., Smith, A. M., West, P. R., et al. (2011). Identifying developmental toxicity pathways for a subset of ToxCast chemicals using human embryonic stem cells and metabolomics. Toxicol Appl Pharmacol 257, 111-121.
44. Kolle, S. N., Ramirez, T., Kamp, H. G., et al. (2012). A testing strategy for the identification of mammalian, systemic endocrine disruptors with particular focus on steroids. Regul Toxicol Pharmacol 63, 259-278.
45. Kremer, M., Henn, A., Kolb, C., et al. (2010). Reduced immunoproteasome formation and accumulation of immunoproteasomal precursors in the brains of lymphocytic choriomeningitis virus-infected mice. J Immunol 185, 5549-5560.
46. Latta, M., Kunstle, G., Leist, M., et al. (2000). Metabolic depletion of ATP by fructose inversely controls CD95- and tumor necrosis factor receptor 1-mediated hepatic apoptosis. J Exp Med 191, 1975-1985.
47. Leist, M., Hartung, T., and Nicotera, P. (2008a). The dawning of a new age of toxicology. ALTEX 25, 103-114.
48. Leist, M., Kadereit, S., and Schildknecht, S. (2008b). Food for thought ... on the real success of 3R approaches. ALTEX 25, 17-32.
49. Leist, M., Efremova, L., and Karreman, C. (2010). Food for thought ... considerations and guidelines for basic test method descriptions in toxicology. ALTEX 27, 309-317.
50. Leist, M., Hasiwa, N., Daneshian, M., et al. (2012a). Validation and quality control of replacement alternatives - current status and future challenges. Toxicol Res 1, 8-22.
51. Leist, M., Lidbury, B. A., Yang, C., et al. (2012b). Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. ALTEX 29, 373-388.
52. Lindon, J. C., Nicholson, J. K., Holmes, E., et al. (2003). Contemporary issues in toxicology the role of metabonomics in toxicology and its evaluation by the COMETproject. Toxicol Appl Pharmacol 187, 137-146.
53. Lindon, J. C., Holmes, E., and Nicholson, J. K. (2004). Metabonomics: systems biology in pharmaceutical research and development. Curr Opin Mol Ther 6, 265-272.
54. Llorach, R., Garcia-Aloy, M., Tulipani, S., et al. (2012). Nutrimetabolomic strategies to develop new biomarkers of intake and health effects. J Agric Food Chem 60, 8797-8808.
55. Louisse, J., Verwei, M., Woutersen, R. A., et al. (2012). Toward in vitro biomarkers for developmental toxicity and their extrapolation to the in vivo situation. Expert Opin Drug Metab Toxicol 8, 11-27.
56. Nguyen, Q. T., Merlo, M. E., Medema, M. H., et al. (2012). Metabolomics methods for the synthetic biology of secondary metabolism. FEBS Lett 586, 2177-2183.
57. Niklas, J., Noor, F., and Heinzle, E. (2009). Effects of drugs in subtoxic concentrations on the metabolic fluxes in human hepatoma cell line Hep G2. Toxicol Appl Pharmacol 240, 327-336.
58. NRC (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington D.C., USA: The National Academies Press. http://www.nap.edu/openbook.php?record-id=11970
59. Patti, G. J., Yanes, O., and Siuzdak, G. (2012). Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13, 263-269.
60. Prot, J. M. And Leclerc, E. (2012). The current status of alternatives to animal testing and predictive toxicology methods using liver microfluidic biochips. Ann Biomed Eng 40, 1228-1243.
61. Rhee, E. P. And Gerszten, R. E. (2012). Metabolomics and cardiovascular biomarker discovery. Clin Chem 58, 139-147.
62. Roede, J. R., Park, Y., Li, S., et al. (2012). Detailed mitochondrial phenotyping by high resolution metabolomics. PLoS One 7, e33020.
63. Ruiz-Aracama, A., Peijnenburg, A., Kleinjans, J., et al. (2011). An untargeted multi-technique metabolomics approach to studying intracellular metabolites of HepG2 cells exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. BMC Genomics 12, 251.
64. Rusyn, I., Sedykh, A., Low, Y., et al. (2012). Predictive modeling of chemical hazard by integrating numerical descriptors of chemical structures and short-term toxicity assay data. Toxicol Sci 127, 1-9.
65. Schildknecht, S., Kirner, S., Henn, A., et al. (2012). Characterization of mouse cell line IMA 2.1 as a potential model system to study astrocyte functions. ALTEX 29, 261-274.
66. Shepherd, L. V., Fraser, P., and Stewart, D. (2011). Metabolomics: a second-generation platform for crop and food analysis. Bioanalysis 3, 1143-1159.
67. Shintu, L., Baudoin, R., Navratil, V., et al. (2012). Metabolomics-on-A-chip and predictive systems toxicology in microfluidic bioartificial organs. Anal Chem 84, 1840-1848.
68. Stephens, M. L., Andersen, M., Becker, R. A., et al. (2013). Evidence-based toxicology for the 21st century: Opportunities and challenges. ALTEX 30, 74-104.
69. Strauss, V., Wiemer, J., Leibold, E., et al. (2009). Influence of strain and sex on the metabolic profile of rats in repeated dose toxicological studies. Toxicol Lett 191, 88-95.
70. Strauss, V., Mellert, W., Wiemer, J., et al. (2012). Increased toxicity when fibrates and statins are administered in combination - a metabolomics approach with rats. Toxicol Lett 211, 187-200.
71. Strigun, A., Noor, F., Pironti, A., et al. (2011a). Metabolic flux analysis gives an insight on verapamil induced changes in central metabolism of HL-1 cells. J Biotechnol 155, 299-307.
72. Strigun, A., Wahrheit, J., Beckers, S., et al. (2011b). Metabolic profiling using HPLC allows classification of drugs according to their mechanisms of action in HL-1 cardiomyocytes. Toxicol Appl Pharmacol 252, 183-191.
73. Strigun, A., Wahrheit, J., Niklas, J., et al. (2012). Doxorubicin increases oxidative metabolism in HL-1 cardiomyocytes as shown by 13C metabolic flux analysis. Toxicol Sci 125, 595-606.
74. Tentschert, J., Draude, F., Jungnickel, H., et al. (in press). TOF-SIMS analysis of cell membrane changes in functional impaired human macrophages after nanosilver treatment. Surface and Interface Analysis.
75. van Ravenzwaay, B., Cunha, G. C., Leibold, E., et al. (2007). The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 172, 21-28.
76. van Ravenzwaay, B., Cunha, G. C., Fabian, E., et al. (2010). The Use of Metabolomics in Cancer Research. In W. C. S. Cho (eds.), An Omics Perspective on Cancer Research. The Netherlands: Springer.
77. van Ravenzwaay, B., Herold, M., Kamp, H., et al. (2012). Metabolomics: a tool for early detection of toxicological effects and an opportunity for biology based grouping of chemicals-from QSAR to QBAR. Mutat Res 746, 144-150.
78. van Vliet, E. (2011). Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century. ALTEX 28, 17-44.
79. Yoon, M., Campbell, J. L., Andersen, M. E., et al. (2012). Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Crit Rev Toxicol 42, 633-652.
80. Zhang, A., Sun, H., Wang, P., et al. (2012a). Recent and potential developments of biofluid analyses in metabolomics. J Proteomics 75, 1079-1088.
81. Zhang, A., Sun, H., and Wang, X. (2012b). Serum metabolomics as a novel diagnostic approach for disease: a systematic review. Anal Bioanal Chem 404, 1239-1245.
82. Zidek, N., Hellmann, J., Kramer, P. J., et al. (2007). Acute hepatotoxicity: a predictive model based on focused illumina microarrays. Toxicol Sci 99, 289-302.ij